Medical Technologies

2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc.

On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension Therapeutics, Inc. for development of an Anti-GPC3 Chimeric Antigen Receptor (CAR) Based on HN3 and YP7 for the Treatment of Human Cancers. Below are the comments KEI submitted to the NIH on June 2th, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 2nd, 2016

David A. Lambertson Ph.D.
Senior Licensing and Patenting Manager,
National Cancer Institute,

2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation

On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Etubics Corporation, for the development and commercialization of adeno-virus based cancer immunotherapy. Below are the comments KEI submitted to the NIH on June 3rd, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 3rd, 2016

Sabarni K. Chatterjee, Ph.D., M.B.A.
Senior Licensing and Patenting Manager,
NCI Technology Transfer Center,
9609 Medical Center Drive, RM 1E530 MSC 9702,

2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation

On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Chimeron Bio Corporation , Inc. for the development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer. Below are the comments KEI submitted to the NIH on June 2th, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 2nd, 2016

Lauren Nguyen-Antczak, Ph.D., J.D.,
Sr. Licensing and Patenting Manager,

2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC

On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to IntelliPanel Medical, LLC. for Anti-TNF Induced Apoptosis (ATIA) Diagnostic Markers and Therapies. Below are the comments KEI submitted to the NIH on June 3rd, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 3rd, 2016

Jaime M. Greene, M.S.,
Senior Licensing and Patenting Manager,
Technology Transfer Center,
National Cancer Institute,
9609 Medical Center Drive, Rockville,MD 20850

2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc.

On May 24th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension Therapeutics, Inc. for the development of an Adeno-Associated Virus Vectors for the Treatment of Glycogen Storage Disease Type Ia. Below are the comments KEI submitted to the NIH on June 8th, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 08, 2016

Surekha Vathyam, Ph.D.
Senior Licensing and Patenting Manager
National Cancer Institute Technology Transfer Center

2016: AAV­Mediated Aquaporin Gene Transfer To Treat Sjögren's Syndrome

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses

May 16th, 2016

Sally Hu, Ph.D., M.B.A.,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and Innovation Access,
National Institute of Dental and Craniofacial Research,
National Institutes of Health,
BLDG 1 DEM, RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817
Telephone: (301) 594-2616
Facsimile: (301) 496-1005
Email: sally.hu@nih.gov.

SCCR32 Day 4: Contributions of the SCCR to the implementation of the respective Development Agenda recommendations

Chair: And I will first invite Nigeria, on behalf of the African Group, to briefly introduce this Agenda Item. Nigeria has the floor. nigeria2.jpg

2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds

More on NIH licensing at http://keionline.org/nih-licenses


May 4, 2016

Betty Tong, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
National Institute of Diabetes and Digestive and Kidney Diseases
12A South Drive,
Bethesda, MD 20892
Via email: betty.tong@nih.gov

May 4, 2016

Dear Dr. Betty Tong,

2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada

These are the April 17, 2016 KEI comments on the NIH proposed exclusive license to Ovensa, for patents on 5T4 antibodies for cancer treatment and diagnosis. (PDF version here)

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


17 April 2016

Rose Freel, Ph.D.
Licensing and Patenting Manager
Technology Transfer Center
National Cancer Institute
8490 Progress Drive, Riverside 5, Suite 400,
Frederick, MD 21702

Syndicate content